NARF-AS1

Across TCGA pan-cancer cohorts, NARF-AS1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of NARF-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where NARF-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NARF-AS1 is over-expressed in tumor.

KIRC, BLCA, and HNSC are the cancer types where NARF-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NARF-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	+0.109	<.001	11	view →
BLCA	All	III,IV	+0.397	<.001	10	view →
HNSC	All	All	+0.071	.002	8	view →
BRCA	All	II,III,IV	+0.268	<.001	6	view →
COAD	All	II,III,IV	+0.200	<.001	6	view →
LUSC	All	All	+0.174	<.001	5	view →
STAD	All	All	+0.361	.001	4	view →
LUAD	All	All	+0.256	<.001	4	view →
CHOL	All	All	+0.588	<.001	2	view →
PRAD	All	All	+0.170	<.001	2	view →
UCEC	All	All	+0.155	.025	2	view →
THCA	Female	All	+0.134	.011	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

NARF-AS1–KIRC

Open the KIRC breakdown →